Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERSIST
2023-505317-25-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of 68Ga FAPI-46 in Crohn's disease, sponsored by Amsterdam University Medical Center. Primary endpoint: Visual and quantitative 68Ga-FAPi-46 uptake in perianal fistula over time. Planned start Jul 2023; status: authorised.
02
Drugs
68Ga FAPI-46
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2023-505317-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505317-25-00.